Amgen Inc.
COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS

Abstract:

The present invention provides combination therapy that includes an KRAS.sup.G12C inhibitor, such as ##STR00001## or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRAS.sup.G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.